Apolipoprotein E polymorphisms and type 2 diabetes: A meta-analysis of 30 studies including 5423 cases and 8197 controls

Molecular Genetics and Metabolism

Volumn 100, Issue 3, 2010, Pages 283-291

  Anthopoulos, P G ^a,b   Hamodrakas, S J ^a   Bagos, P G ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b University of Central   (Greece)

Author keywords

Apolipoprotein E; Meta analysis; Multivariate methods; Polymorphism; Random effects; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE PREDISPOSITION; DYSLIPIDEMIA; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; METABOLIC DISORDER; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REGRESSION ANALYSIS; RISK ASSESSMENT; UNIVARIATE ANALYSIS;

ALLELES; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPIDS; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 77953026034     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.03.008     Document Type: Article

References (98)

1. Hu F.B. Sedentary lifestyle and risk of obesity and type 2 diabetes. Lipids 38 (2003) 103-108
2. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
3. Rosenbloom A.L., Joe J.R., Young R.S., and Winter W.E. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22 (1999) 345-354
4. Ehm M.G., Karnoub M.C., Sakul H., Gottschalk K., Holt D.C., Weber J.L., Vaske D., Briley D., Briley L., Kopf J., McMillen P., Nguyen Q., Reisman M., Lai E.H., Joslyn G., Shepherd N.S., Bell C., Wagner M.J., and Burns D.K. Genomewide search for type 2 diabetes susceptibility genes in four American populations. Am. J. Hum. Genet. 66 (2000) 1871-1881
5. Sookoian S., Gianotti T.F., Schuman M., and Pirola C.J. Gene prioritization based on biological plausibility over genome wide association studies renders new loci associated with type 2 diabetes. Genet. Med. (2009)
6. McCarthy M.I., and Zeggini E. Genome-wide association studies in type 2 diabetes. Curr. Diab. Rep. 9 (2009) 164-171
7. Barroso I. Genetics of type 2 diabetes. Diabet. Med. 22 (2005) 517-535
8. Busch C.P., and Hegele R.A. Genetic determinants of type 2 diabetes mellitus. Clin. Genet. 60 (2001) 243-254
9. Malecki M.T. Genetics of type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 68 Suppl. 1 (2005) S10-21
10. Hill J.M., Bhattacharjee P.S., and Neumann D.M. Apolipoprotein E alleles can contribute to the pathogenesis of numerous clinical conditions including HSV-1 corneal disease. Exp. Eye Res. 84 (2007) 801-811
11. Mahley R.W., and Rall Jr. S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1 (2000) 507-537
12. Eichner J.E., Dunn S.T., Perveen G., Thompson D.M., Stewart K.E., and Stroehla B.C. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155 (2002) 487-495
13. Siest G., Pillot T., Regis-Bailly A., Leininger-Muller B., Steinmetz J., Galteau M.M., and Visvikis S. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin. Chem. 41 (1995) 1068-1086
14. Rall Jr. S.C., and Mahley R.W. The role of apolipoprotein E genetic variants in lipoprotein disorders. J. Intern. Med. 231 (1992) 653-659
15. Ribalta J., Vallve J.C., Girona J., and Masana L. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr. Opin. Clin. Nutr. Metab. Care 6 (2003) 177-187
16. de Knijff P., van den Maagdenberg A.M., Frants R.R., and Havekes L.M. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum. Mutat. 4 (1994) 178-194
17. Hagberg J.M., Wilund K.R., and Ferrell R.E. APO E gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol. Genomics 4 (2000) 101-108
18. Greenow K., Pearce N.J., and Ramji D.P. The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. 83 (2005) 329-342
19. Weintraub M.S., Eisenberg S., and Breslow J.L. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J. Clin. Invest. 80 (1987) 1571-1577
20. Song Y., Stampfer M.J., and Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 141 (2004) 137-147
21. Wilson P.W., Schaefer E.J., Larson M.G., and Ordovas J.M. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1250-1255
22. McCarron M.O., Delong D., and Alberts M.J. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology 53 (1999) 1308-1311
23. Bennet A.M., Di Angelantonio E., Ye Z., Wensley F., Dahlin A., Ahlbom A., Keavney B., Collins R., Wiman B., de Faire U., and Danesh J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298 (2007) 1300-1311
24. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., and van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278 (1997) 1349-1356
25. Huang X., Chen P., Kaufer D.I., Troster A.I., and Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch. Neurol. 63 (2006) 189-193
26. Thakkinstian A., Bowe S., McEvoy M., Smith W., and Attia J. Association between apolipoprotein E polymorphisms and age-related macular degeneration: a HuGE review and meta-analysis. Am. J. Epidemiol. 164 (2006) 813-822
27. Small B.J., Rosnick C.B., Fratiglioni L., and Backman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol. Aging 19 (2004) 592-600
28. Windler E. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome?. Atheroscler. Suppl. 6 (2005) 11-14
29. Taskinen M.R. Diabetic dyslipidemia. Atheroscler. Suppl. 3 (2002) 47-51
30. McAuley L., Pham B., Tugwell P., and Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?. Lancet 356 (2000) 1228-1231
31. Pan Z., Trikalinos T.A., Kavvoura F.K., Lau J., and Ioannidis J.P. Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med. 2 (2005) e334
32. Greenland S. Meta-analysis. In: Rothman K.J., and Greenland S. (Eds). Modern Epidemiology (1998), Lippincott Williams & Wilkins 643-673
33. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., and Thacker S.B. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000) 2008-2012
34. Thompson S.G., and Higgins J.P. How should meta-regression analyses be undertaken and interpreted?. Stat. Med. 21 (2002) 1559-1573
35. Bagos P.G. A unification of multivariate methods for meta-analysis of genetic association studies. Stat. Appl. Genet. Mol. Biol. 7 (2008) (Article 31)
36. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986) 177-188
37. Petiti D.B. Meta-Analysis Decision Analysis and Cost-Effectiveness Analysis (1994), Oxford University Press
38. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
39. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994) 1088-1101
40. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
41. Thompson S.G., and Sharp S.J. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat. Med. 18 (1999) 2693-2708
42. Lau J., Schmid C.H., and Chalmers T.C. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J. Clin. Epidemiol. 48 (1995) 45-57 (discussion 59-60)
43. Lau J., Antman E.M., Jimenez-Silva J., Kupelnick B., Mosteller F., and Chalmers T.C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N. Engl. J. Med. 327 (1992) 248-254
44. Ioannidis J.P., and Trikalinos T.A. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. J. Clin. Epidemiol. 58 (2005) 543-549
45. Bagos P.G., and Nikolopoulos G.K. Generalized least squares for assessing trends in cumulative meta-analysis with applications in genetic epidemiology. J. Clin. Epidemiol. 62 (2009) 1037-1044
46. Trikalinos T.A., Salanti G., Khoury M.J., and Ioannidis J.P. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am. J. Epidemiol. 163 (2006) 300-309
47. Guo S.W., and Thompson E.A. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48 (1992) 361-372
48. Kamboh M.I., Aston C.E., and Hamman R.F. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis 112 (1995) 145-159
49. del Pozo C., Serrat J., Homs R., Sorribas A., and Gomez J.A. Polymorphism of apolipoprotein E in non-insulin dependent diabetes mellitus. Med. Clin. (Barc.) 91 (1988) 289-292
50. Xiang G.D., Hu T.H., and Wang Y.L. Apolipoprotein E genotypes and carotid artery atherosclerosis in type 2 diabetes mellitus. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 20 (2003) 66-68
51. Zhang X., Liu B., Bai H., Tian H., Wu Z., Zhang R., Fang D., Xu Y., Yao J., and Ren Y. Study on apolipoprotein E gene polymorphism in Chinese type 2 diabetes mellitus. Sichuan Da Xue Xue Bao Yi Xue Ban 34 (2003) 75-77
52. Camsari A., Tamer L., Aras Ates N., Pekdemir H., Cicek D., Ercan B., Camdeviren H., and Atik U. Apolipoprotein E polymorphism in diabetic and non-diabetic patients: does it really contribute to atherosclerosis?. Acta Cardiol. 60 (2005) 409-414
53. Eto M., Watanabe K., Iwashima Y., Morikawa A., Chonan N., Oshima E., Sekiguchi M., and Ishii K. Increased frequency of apolipoprotein epsilon 4 allele in type II diabetes with hypercholesterolemia. Diabetes 36 (1987) 1301-1306
54. Guangda X., Bangshun X., Xiujian L., and Yangzhong H. Apovarepsilon(4) allele increases the risk for exercise-induced silent myocardial ischemia in non-insulin-dependent diabetes mellitus. Atherosclerosis 147 (1999) 293-296
55. Hsieh M.C., Lin S.R., Yang Y.C., Chen H.C., Lin J.N., and Shin S.J. Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J. Nephrol. 15 (2002) 368-373
56. Inamdar P.A., Kelkar S.M., Devasagayam T.P., and Bapat M.M. Apolipoprotein E polymorphism in non-insulin-dependent diabetics of Mumbai, India and its effect on plasma lipids and lipoproteins. Diabetes Res. Clin. Pract. 47 (2000) 217-223
57. Kalix B., Meynet M.C., Garin M.C., and James R.W. The apolipoprotein epsilon2 allele and the severity of coronary artery disease in type 2 diabetic patients. Diabet. Med. 18 (2001) 445-450
58. Vaisi-Raygani A., Rahimi Z., Nomani H., Tavilani H., and Pourmotabbed T. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin. Biochem. 40 (2007) 1150-1156
59. Eto M., Horita K., Morikawa A., Nakata H., Okada M., Saito M., Nomura M., Abiko A., Iwashima Y., Ikoda A., et al. Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin. Genet. 48 (1995) 288-292
60. Eto M., Watanabe K., Iwashima Y., Morikawa A., Oshima E., Sekiguchi M., and Ishii K. Apolipoprotein E polymorphism and hyperlipemia in type II diabetics. Diabetes 35 (1986) 1374-1382
61. Horita K., Eto M., and Makino I. Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 107 (1994) 203-211
62. Ioannidis J.P. Genetic associations: false or true?. Trends Mol. Med. 9 (2003) 135-138
63. Ioannidis J.P., Trikalinos T.A., and Khoury M.J. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am. J. Epidemiol. 164 (2006) 609-614
64. Ioannidis J.P., Trikalinos T.A., Ntzani E.E., and Contopoulos-Ioannidis D.G. Genetic associations in large versus small studies: an empirical assessment. Lancet 361 (2003) 567-571
65. Zeggini E., Weedon M.N., Lindgren C.M., Frayling T.M., Elliott K.S., Lango H., Timpson N.J., Perry J.R., Rayner N.W., Freathy R.M., Barrett J.C., Shields B., Morris A.P., Ellard S., Groves C.J., Harries L.W., Marchini J.L., Owen K.R., Knight B., Cardon L.R., Walker M., Hitman G.A., Morris A.D., Doney A.S., McCarthy M.I., and Hattersley A.T. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316 (2007) 1336-1341
66. Scott L.J., Mohlke K.L., Bonnycastle L.L., Willer C.J., Li Y., Duren W.L., Erdos M.R., Stringham H.M., Chines P.S., Jackson A.U., Prokunina-Olsson L., Ding C.J., Swift A.J., Narisu N., Hu T., Pruim R., Xiao R., Li X.Y., Conneely K.N., Riebow N.L., Sprau A.G., Tong M., White P.P., Hetrick K.N., Barnhart M.W., Bark C.W., Goldstein J.L., Watkins L., Xiang F., Saramies J., Buchanan T.A., Watanabe R.M., Valle T.T., Kinnunen L., Abecasis G.R., Pugh E.W., Doheny K.F., Bergman R.N., Tuomilehto J., Collins F.S., and Boehnke M. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316 (2007) 1341-1345
67. Saxena R., Voight B.F., Lyssenko V., Burtt N.P., de Bakker P.I., Chen H., Roix J.J., Kathiresan S., Hirschhorn J.N., Daly M.J., Hughes T.E., Groop L., Altshuler D., Almgren P., Florez J.C., Meyer J., Ardlie K., Bengtsson Bostrom K., Isomaa B., Lettre G., Lindblad U., Lyon H.N., Melander O., Newton-Cheh C., Nilsson P., Orho-Melander M., Rastam L., Speliotes E.K., Taskinen M.R., Tuomi T., Guiducci C., Berglund A., Carlson J., Gianniny L., Hackett R., Hall L., Holmkvist J., Laurila E., Sjogren M., Sterner M., Surti A., Svensson M., Tewhey R., Blumenstiel B., Parkin M., Defelice M., Barry R., Brodeur W., Camarata J., Chia N., Fava M., Gibbons J., Handsaker B., Healy C., Nguyen K., Gates C., Sougnez C., Gage D., Nizzari M., Gabriel S.B., Chirn G.W., Ma Q., Parikh H., Richardson D., Ricke D., and Purcell S. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316 (2007) 1331-1336
68. E. Zeggini, L.J. Scott, R. Saxena, B.F. Voight, J.L. Marchini, T. Hu, P.I. de Bakker, G.R. Abecasis, P. Almgren, G. Andersen, K. Ardlie, K.B. Bostrom, R.N. Bergman, L.L. Bonnycastle, K. Borch-Johnsen, N.P. Burtt, H. Chen, P.S. Chines, M.J. Daly, P. Deodhar, C.J. Ding, A.S. Doney, W.L. Duren, K.S. Elliott, M.R. Erdos, T.M. Frayling, R.M. Freathy, L. Gianniny, H. Grallert, N. Grarup, C.J. Groves, C. Guiducci, T. Hansen, C. Herder, G.A. Hitman, T.E. Hughes, B. Isomaa, A.U. Jackson, T. Jorgensen, A. Kong, K. Kubalanza, F.G. Kuruvilla, J. Kuusisto, C. Langenberg, H. Lango, T. Lauritzen, Y. Li, C.M. Lindgren, V. Lyssenko, A.F. Marvelle, C. Meisinger, K. Midthjell, K.L. Mohlke, M.A. Morken, A.D. Morris, N. Narisu, P. Nilsson, K.R. Owen, C.N. Palmer, F. Payne, J.R. Perry, E. Pettersen, C. Platou, I. Prokopenko, L. Qi, L. Qin, N.W. Rayner, M. Rees, J.J. Roix, A. Sandbaek, B. Shields, M. Sjogren, V. Steinthorsdottir, H.M. Stringham, A.J. Swift, G. Thorleifsson, U. Thorsteinsdottir, N.J. Timpson, T. Tuomi, J. Tuomilehto, M. Walker, R.M. Watanabe, M.N. Weedon, C.J. Willer, T. Illig, K. Hveem, F.B. Hu, M. Laakso, K. Stefansson, O. Pedersen, N.J. Wareham, I. Barroso, A.T. Hattersley, F.S. Collins, L. Groop, M.I. McCarthy, M. Boehnke, D. Altshuler, Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes, Nat. Genet. 40 (2008) 638-645.
69. Sterne J.A., Gavaghan D., and Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J. Clin. Epidemiol. 53 (2000) 1119-1129
70. Ioannidis J.P., Ntzani E.E., Trikalinos T.A., and Contopoulos-Ioannidis D.G. Replication validity of genetic association studies. Nat. Genet. 29 (2001) 306-309
71. Dallongeville J., Lussier-Cacan S., and Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J. Lipid Res. 33 (1992) 447-454
72. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., and Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 263 (1990) 2893-2898
73. Pendse A.A., Arbones-Mainar J.M., Johnson L.A., Altenburg M., and Maeda N. ApoE knock-out and knock-in mice: atherosclerosis, metabolic syndrome and beyond. J. Lipid Res. (2008)
74. Karagiannides I., Abdou R., Tzortzopoulou A., Voshol P.J., and Kypreos K.E. Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. FEBS J. 275 (2008) 4796-4809
75. Gao J., Katagiri H., Ishigaki Y., Yamada T., Ogihara T., Imai J., Uno K., Hasegawa Y., Kanzaki M., Yamamoto T.T., Ishibashi S., and Oka Y. Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 56 (2007) 24-33
76. Arbones-Mainar J.M., Johnson L.A., Altenburg M.K., and Maeda N. Differential modulation of diet-induced obesity and adipocyte functionality by human apolipoprotein E3 and E4 in mice. Int. J. Obes. (Lond.) 32 (2008) 1595-1605
77. Schmid C.H., Stark P.C., Berlin J.A., Landais P., and Lau J. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J. Clin. Epidemiol. 57 (2004) 683-697
78. Higgins J.P., and Thompson S.G. Controlling the risk of spurious findings from meta-regression. Stat. Med. 23 (2004) 1663-1682
79. McAteer J.B., Prudente S., Bacci S., Lyon H.N., Hirschhorn J.N., Trischitta V., and Florez J.C. The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects. Diabetes 57 (2008) 1125-1130
80. Ludovico O., Pellegrini F., Di Paola R., Minenna A., Mastroianno S., Cardellini M., Marini M.A., Andreozzi F., Vaccaro O., Sesti G., and Trischitta V. Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk. Obesity (Silver Spring) 15 (2007) 1076-1081
81. Minelli C., Thompson J.R., Tobin M.D., and Abrams K.R. An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. Am. J. Epidemiol. 160 (2004) 445-452
82. Lawlor D.A., Harbord R.M., Sterne J.A., Timpson N., and Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat. Med. 27 (2008) 1133-1163
83. Vogelberg K.H., and Maucy E. Apo E 2 phenotypes in type II diabetics with and without insulin therapy. Klin. Wochenschr. 66 (1988) 690-693
84. Imari Y., Koga S., and Ibayashi H. Phenotypes of apolipoprotein E and abnormalities in lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 37 (1988) 1134-1138
85. Shriver M.D., Boerwinkle E., Hewett-Emmett D., and Hanis C.L. Frequency and effects of apolipoprotein E polymorphism in Mexican-American NIDDM subjects. Diabetes 40 (1991) 334-337
86. Boemi M., James R.W., Romagnoli F., Gerber P., Pometta D., and Fumelli P. Gender differences in a type 2 (non-insulin-dependent) diabetic population with respect to apolipoprotein E phenotype frequencies. Diabetologia 36 (1993) 229-233
87. Vauhkonen I., Niskanen L., Ryynanen M., Voutilainen R., Partanen J., Toyry J., Mercuri M., Rauramaa R., and Uusitupa M. Divergent association of apolipoprotein E polymorphism with vascular disease in patients with NIDDM and control subjects. Diabet. Med. 14 (1997) 748-756
88. Kimura H., Suzuki Y., Gejyo F., Karasawa R., Miyazaki R., Suzuki S., and Arakawa M. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am. J. Kidney Dis. 31 (1998) 666-673
89. Santos A., Salguero M.L., Gurrola C., Munoz F., Roig-Melo E., and Panduro A. The epsilon4 allele of apolipoprotein E gene is a potential risk factor for the severity of macular edema in type 2 diabetic Mexican patients. Ophthalmic Genet. 23 (2002) 13-19
90. Liu L., Xiang K., Zheng T., Zhang R., Li M., and Li J. Co-inheritance of specific genotypes of HSPG and ApoE gene increases risk of type 2 diabetic nephropathy. Mol. Cell. Biochem. 254 (2003) 353-358
91. Powell D.S., Maksoud H., Charge S.B., Moffitt J.H., Desai M., Da Silva Fihlo R.L., Hattersley A.T., Stratton I.M., Matthews D.R., Levy J.C., and Clark A. Apolipoprotein E genotype, islet amyloid deposition and severity of type 2 diabetes. Diabetes Res. Clin. Pract. 60 (2003) 105-110
92. Duman B.S., Ozturk M., Yilmazer S., and Hatemi H. Apolipoprotein E polymorphism in Turkish subjects with type 2 diabetes mellitus: allele frequency and relation to serum lipid concentrations. Diabetes Nutr. Metab. 17 (2004) 267-274
93. Leiva E., Mujica V., Orrego R., Prieto M., and Arredondo M. Apolipoprotein E polymorphism in type 2 diabetic patients of Talca, Chile. Diabetes Res. Clin. Pract. 68 (2005) 244-249
94. Errera F.I., Silva M.E., Yeh E., Maranduba C.M., Folco B., Takahashi W., Pereira A.C., Krieger J.E., and Passos-Bueno M.R. Effect of polymorphisms of the MTHFR and APOE genes on susceptibility to diabetes and severity of diabetic retinopathy in Brazilian patients. Braz. J. Med. Biol. Res. 39 (2006) 883-888
95. Morbois-Trabut L., Chabrolle C., Garrigue M.A., Lasfargues G., and Lecomte P. Apolipoprotein E genotype and plasma lipid levels in Caucasian diabetic patients. Diabetes Metab. 32 (2006) 270-275
96. Singh P.P., Naz I., Gilmour A., Singh M., and Mastana S. Association of APOE (Hha1) and ACE (I/D) gene polymorphisms with type 2 diabetes mellitus in North West India. Diabetes Res. Clin. Pract. 74 (2006) 95-102
97. Ilhan N., Kahraman N., Seckin D., and Colak R. Apo E gene polymorphism on development of diabetic nephropathy. Cell Biochem. Funct. 25 (2007) 527-532
98. Kwon M.K., Rhee S.Y., Chon S., Oh S., Woo J.T., Kim S.W., Kim J.W., Kim Y.S., Jeong K.H., Lee S.H., Lee T.W., and Ihm C.G. Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res. Clin. Pract. 77 Suppl. 1 (2007) S228-S232